Solventum's fundamental outlook is constrained by flat revenue growth (ranging from -3.7% to +3.8% over the past two years) and deteriorating cash generation, with free cash flow turning negative at -$129M in 2026Q2 versus +$340M in 2024Q1. While the company h...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth has stalled near zero (latest quarter +2.2%), while gross margin improved to 58.2% but operating margin compressed to 8.2% from 18.9% in 2024Q1, reflecting a 55% rise in SG&A costs.
Solventum Corporation has a rich history of over 70 years in healthcare innovations, positioning it as a leader in the medical instruments and supplies sector.
With $8.3 billion in sales in 2024, Solventum demonstrates robust financial health and market presence.
Bullish investment theses and recommendations to hold SOLV stock indicate strong analyst confidence in its growth potential.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | $2.55+34.2% vs $1.90 | $2.2B+2.6% vs $2.2B |
Q2 2026 May 5, 2026 | $1.48+9.6% vs $1.35 | $2.0B+2.0% vs $2.0B |
Q1 2026 Feb 26, 2026 | $1.57+4.7% vs $1.50 | $2.0B+1.8% vs $2.0B |
Q4 2025 Nov 6, 2025 | $1.50+4.9% vs $1.43 | $2.1B+2.0% vs $2.1B |
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
Solventum Corporation (SOLV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Solventum (SOLV) reported earnings 30 days ago. What's next for the stock?
EAGAN, Minn., Sept. 2, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that management will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, Sept.
Benchmark SOLV against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Solventum Corporation (SOLV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $88.37 | $15.3B | 9.95 | 0.86% | 18.69% | 38.86% | — | |
| $23.49 | $12.13B | -13.42 | 5.72% | -9.27% | -16.67% | — | |
| $182.52 | $50.29B | 31.31 | 8.23% | 4.52% | 3.79% | — | |
| $56.07 | $10.94B | 29.98 | 5.06% | 13.46% | 6.88% | — | |
| $76.01 | $16.97B | 30.53 | 1.74% | 13.18% | 11.01% | — | |
| $3.53 | $14.42M | -0.60 | 814.07% | -795.5% | -162.75% | — |
Solventum Corporation (SOLV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Solventum Corporation (SOLV) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Aug 5, 2026·SEC
Jul 20, 2026·SEC
Get notified when SOLV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Solventum Corporation (SOLV) stock FAQ — growth, dividends, profitability & financials explained
Solventum Corporation (SOLV) reported $8.31B in revenue for fiscal year 2025. This represents a 2% increase from $8.17B in 2021.
Solventum Corporation (SOLV) grew revenue by 0.9% over the past year. Growth has been modest.
Yes, Solventum Corporation (SOLV) is profitable, generating $1.43B in net income for fiscal year 2025 (18.7% net margin).
Solventum Corporation (SOLV) has a return on equity (ROE) of 38.9%. This is excellent, indicating efficient use of shareholder capital.
Solventum Corporation (SOLV) had negative free cash flow of $391.0M in fiscal year 2025, likely due to heavy capital investments.
